目的 探讨脑小血管病患者血清磷酸化Tau蛋白-181（P-Tau181）、γ-谷氨酰转肽酶（GGT）、沉默信息调节因子1（SIRT1）与睡眠障碍的相关性。 方法 将156例脑小血管病患者按照PSQI评分分为睡眠障碍组（PSQI ≥ 10分）与睡眠正常组（PSQI < 10分）。比较两组的血清P-Tau181、GGT、SIRT1水平，分析血清P-Tau181、GGT、SIRT1对脑小血管病患者发生睡眠障碍的预测价值。 结果 156例脑小血管病患者中睡眠障碍52例，占比33.33%，PSQI评分高于睡眠正常组（P＜0.05）。睡眠障碍组的血清P-Tau181、GGT、SIRT1高于睡眠正常组（P < 0.05）。P-Tau181、GGT、SIRT1与PSQI评分呈正相关（P < 0.05）。P-Tau181、GGT、SIRT1单一及联合预测脑小血管病患者发生睡眠障碍的曲线下面积分别为0.672、0.742、0.749、0.843。 结论 P-Tau181、GGT、SIRT1异常表达与脑小血管病患者发生睡眠障碍有关。

Objective To explore the correlation between serum phosphorylated Tau protein-181 （P-Tau181）， gamma glutamyl transpeptidase （GGT）， silent information regulator 1（SIRT1） and sleep disorders in patients with cerebral small vessel disease. Methods A total of 156 patients with cerebral small vessel disease （CSVD） were divided into a sleep disorder group （PSQI ≥ 10） and a normal sleep group （PSQI < 10） based on the Pittsburgh Sleep Quality Index （PSQI） scores. Serum levels of P-Tau181， GGT， and SIRT1 were compared between the two groups， and the predictive value of these biomarkers for the development of sleep disorders in CSVD patients was analyzed. Results Among 156 patients with cerebral small vessel disease （CSVD）， 52（33.33%） were diagnosed with sleep disorders， and their Pittsburgh Sleep Quality Index （PSQI） scores were significantly higher than those of the normal sleep group （P < 0.05）. The serum levels of P-Tau181， GGT， and SIRT1 in the sleep disorder group were elevated compared to the normal sleep group （P < 0.05）. Positive correlations were observed between PSQI scores and P-Tau181， GGT， and SIRT1 levels （P < 0.05）. The areas under the curve （AUC） for predicting sleep disorders in CSVD patients using individual biomarkers （P-Tau181， GGT， SIRT1） and their combined prediction were 0.672， 0.742， 0.749， and 0.843， respectively. Conclusion The abnormal expression of P-Tau181， GGT， and SIRT1 is associated with sleep disorders in patients with cerebral small vessel disease.